PHARMACY

Decision Resources projects modest growth for UC drug market

BY Allison Cerra

BURLINGTON, Mass. The drug market for ulcerative colitis treatments will see modest growth through 2019, according to a new report by Decision Resources.

The research and advisory firm said that the UC drug market will see growth of $800 million, driven by the uptake of Abbott and Eisai’s Humira, Centocor Ortho Biotech/Merck/Mitsubishi Tanabe Pharma/Janssen’s Simponi and Millennium’s vedolizumab in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

A report by Pharmacor also noted that the market will grow as the prevalence of ulcerative colitis in the United States has risen, but drug failures in late-stage clinical trials have plagued the clinical development of additional therapies for moderate to severe ulcerative colitis, where the greatest level of unmet need remains.

"Although several agents are in mid- to late-stage clinical development for ulcerative colitis, interviewed thought leaders consider the cell adhesion molecule inhibitor vedolizumab to be one of the most promising emerging therapies with a novel mechanism of action," said Decision Resources analyst Bingnan Kang. "Phase-3 clinical trials for vedolizumab in ulcerative colitis and Crohn’s disease are currently under way in both the United States and Europe."

Back in February, Decision Resources projected that the market for drugs to treat ulcerative colitis could almost double within less than 10 years.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

J&J receives complete response letter for tapentadol ER

BY Alaric DeArment

RARITAN, N.J. The Food and Drug Administration turned down a regulatory approval application from Johnson & Johnson for a drug to treat chronic pain, J&J said Monday.

 

The drug maker said the FDA issued a complete response letter for tapentadol extended-release tablets. The agency is requesting data concerning the conversion of the extended-release formulation of the drug used in clinical trials to a different formulation designed to increase the drug’s resistance to breaking or crushing by drug abusers. The FDA issues a complete response letter when it needs more data before it can approve a drug.

 

 

“We will engage the FDA in active discussions as quickly as possible so that we can address the requests in the complete response letter,” Johnson & Johnson pharmaceutical research and development therapeutic area head for analgesia Juergen Haeussler said. “We remain fully committed to bringing tapentadol ER to patients experiencing chronic pain as quickly as possible.”

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

NCPA to HHS: Ensure patients’ access to pharmacies, enforce transparency rules for PBMs

BY Alaric DeArment

ALEXANDRIA, Va. The lobby for the country’s independent pharmacies is urging the Department of Health and Human Services to ensure patients’ access to community pharmacies and enforce transparency rules for pharmacy benefit managers.

The National Community Pharmacists Association said Monday that it had asked HHS to adopt minimum pharmacy access standards in healthcare insurance exchanges. The NCPA also argued against tiered co-payments that favor one pharmacy provider, such as mail order, over others, and argued in favor of allowing any pharmacy willing to accept the terms of the pharmacy contract to participate.

The healthcare-reform law requires PBMs operating in the health-insurance exchanges to confidentially report such information as the percentage of all prescriptions provided through retail pharmacies compared with mail order, and the generic dispensing and substitution rates of each; the aggregate amount and types of rebates, discounts and price concessions that the PBM negotiates on behalf of the plan and the aggregate amount passed on to the plan sponsor; and the average aggregate difference between the amount the plan pays the PBM and the amount the PBM pays the retail and mail-order pharmacy.

“Access to this critical information will enable the [HHS secretary] and the health plans to better evaluate and, in turn, negotiate contracts for prescription drug benefit administration in order to contain costs and maximize consumer protections,” the NCPA said in its comments to HHS. “To date, there has been no clear direction as to where these new federal PBM discloser requirements should be included.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?